|
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
Together, our results highlight the importance of epithelial-specific MyD88 signaling and demonstrate that although functional MyD88 signaling in DC and macrophages alone is sufficient to correct the phenotype of MyD88-deficiency, these cells do not seem to be essential for host protection in MyD88-sufficient animals during acute infection with C. difficile.
|
30802297 |
2019 |
|
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
All these responses were abrogated in mice with a general deficiency of MyD88 but unaltered in mice with MyD88 deficiency, specifically in myeloid or type II lung epithelial cells.
|
27625307 |
2017 |
|
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
While myeloid differentiation factor 88 (MyD88) is also a crucial adaptor for most TLR signaling pathways, MyD88 deficiency had only a marginal impact on disease course.
|
29568058 |
2018 |
|
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
As MyD88(-/-) BMDM exhibit low surface expression of dectin-1 after in vitro culture in rMCSF, differences in dectin-1 dependent, MyD88-independent signaling may account for some of the phenotypes currently ascribed to MyD88-deficiency alone.
|
17997408 |
2008 |
|
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
Because MyD88 is essential for the downstream signaling of all TLRs, except TLR3, we investigated the effects of MyD88 deficiency (MyD88-/-) on behavioral functions in mice.
|
22051943 |
2012 |
|
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
The comparison of disease development in mice carrying the hematopoietic cell-specific deletion of MyD88 (<i>Myd88<sup>fl/fl</sup>Vav-cre<sup>+</sup></i> mice) with mice carrying the total MyD88 deficiency (<i>Myd88</i><sup>-/-</sup> mice), we show that the progression of skin and systemic inflammation, as well as of epidermal thickening, was completely dependent on MyD88 expression in hematopoietic cells.
|
28642279 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
MyD88-loaded EVs were detected in the bone marrow aspirates of WM patients thus establishing the physiological role of EVs for MyD88<sup>L265P</sup> transmission and shaping of the proinflammatory microenvironment.
|
29358175 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Identification of highly recurrent activating somatic mutation in MYD88 has improved our understanding of the pathogenesis of Waldenström macroglobulinemia and has therapeutic implications.
|
26196236 |
2015 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 L265P was absent in paired normal tissue samples from patients with Waldenström's macroglobulinemia or non-IgM LPL and in B cells from healthy donors and was absent or rarely expressed in samples from patients with multiple myeloma, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.
|
22931316 |
2012 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to establish an unlabeled probe genotyping approach for rapid detection of the MYD88 L265P mutation in the differential diagnosis of Waldenstrӧm macroglobulinemia patients.
|
25462104 |
2015 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The two MYD88 wild type LPL cases were associated with cold agglutinin disease.
|
25819228 |
2015 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
|
27840426 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
|
24224040 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This review discusses the role of MYD88 L265P mutations as well as targets beyond MYD88 in the setting of pathogenesis and development of future rational therapeutic trials focusing on patients diagnosed with WM.
|
24573383 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the absence of the MyD88 L265P somatic mutation in our SS cohort does not exclude a common germline susceptibility gene in SS, it might suggest a distinct operating pathogenetic mechanism in SS-related lymphoma compared with WM and other hematological malignancies.
|
24153350 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The findings support that HCK expression and activation is triggered by mutated MYD88, supports the growth and survival of mutated MYD88 WM and ABC DLBCL cells, and is a direct target of ibrutinib.
|
27143257 |
2016 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, in this small case series we showed that MYD88 L265P mutation analysis could serve as a useful adjunct in distinguishing benign from lymphomatous PE in patients with LPL.
|
31556196 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recent molecular studies have identified mutations in the MYD88 and CXCR4 genes as early events in the pathogenesis of IgM MGUS and Waldenström's macroglobulinemia.
|
27825465 |
2016 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
This review discusses the molecular and biological mechanisms underlying MYD88 mutations in LPL/WM, the role of MYD88 mutations as molecular biomarker for the refinement of diagnosis and the improvement classification of LPL/WM, and novel targeted therapeutic strategies for LPL/WM based on the pharmacological manipulation of MYD88 signaling to which this lymphoma is addicted.
|
25696843 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These studies show the feasibility for detecting MYD88 L265P by PB examination, and the potential for PB MYD88 L265P ΔCt use in the diagnosis and management of WM patients.
|
24509637 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> Everolimus inhibits mTOR, a component of PI3K/AKT prosurvival signaling triggered by MYD88 and CXCR4-activating mutations in Waldenstrom macroglobulinemia.<b>Experimental design:</b> We evaluated everolimus in a prospective, multicenter study of 33 symptomatic, previously untreated Waldenstrom macroglobulinemia patients.
|
27836860 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Whole-genome sequencing has revealed MYD88 L265P and CXCR4 mutations (CXCR4(mut)) as the most prevalent somatic mutations in Waldenström macroglobulinemia.
|
26490317 |
2016 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B-cell lymphoproliferative disorders (B-LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation.
|
30198568 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The MYD88 L265P mutation is present in nearly 90% of patients with Waldenström macroglobulinemia.
|
30190015 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
|
30401751 |
2018 |